[HTML][HTML] Application of intranasal administration in the delivery of antidepressant active ingredients
Z Jin, Y Han, D Zhang, Z Li, Y Jing, B Hu, S Sun - Pharmaceutics, 2022 - mdpi.com
As a mental disease in modern society, depression shows an increasing occurrence, with
low cure rate and high recurrence rate. It has become the most disabling disease in the …
low cure rate and high recurrence rate. It has become the most disabling disease in the …
Efficacy and tolerability of desvenlafaxine in the real-world treatment of patients with major depression: a narrative review and an expert opinion paper
Introduction Major depressive disorder (MDD) is a common severe mental disorder,
requiring a tailored and integrated treatment. Several approaches are available including …
requiring a tailored and integrated treatment. Several approaches are available including …
[HTML][HTML] Impact of polymorphisms in CYP and UGT enzymes and ABC and SLCO1B1 transporters on the pharmacokinetics and safety of desvenlafaxine
S Calleja, P Zubiaur, D Ochoa… - Frontiers in …, 2023 - frontiersin.org
Venlafaxine pharmacokinetic variability and pharmacotherapy outcomes are well known to
be related to CYP2D6 pharmacogenetic phenotype. In contrast, scarce pharmacogenetic …
be related to CYP2D6 pharmacogenetic phenotype. In contrast, scarce pharmacogenetic …
[HTML][HTML] A multicenter, randomized, double-blind, duloxetine-controlled, non-inferiority trial of desvenlafaxine succinate extended-release in patients with major …
Q Zhao, B Fu, N Lyu, X Xu, G Huang, Y Tan… - Journal of Affective …, 2023 - Elsevier
Background Desvenlafaxine and duloxetine are selective serotonin and norepinephrine
reuptake inhibitors. Their efficacy has not been directly compared using statistical …
reuptake inhibitors. Their efficacy has not been directly compared using statistical …
A fatal case of desvenlafaxine and paroxetine poisoning
S Jeong, Y Kim, S Choe, H Kang, HM Kim… - … of pharmaceutical and …, 2024 - Elsevier
Desvenlafaxine (O-desmethylvenlafaxine) and paroxetine are antidepressants that inhibit
serotonin reuptake. Despite their relatively safe profiles, several serious side effects …
serotonin reuptake. Despite their relatively safe profiles, several serious side effects …
Antidepressants in People with Chronic Liver Disease and Depression: When are they warranted and how to choose the suitable one?
S Sahoo, E Mishra, M Premkumar - Journal of Clinical and Experimental …, 2024 - Elsevier
Most chronic medical illnesses are associated with significant psychiatric comorbidity,
especially in the form of depression, anxiety, and suicidality. Chronic liver disease (CLD) is …
especially in the form of depression, anxiety, and suicidality. Chronic liver disease (CLD) is …
The Pharmacokinetics and Bioequivalence of Desvenlafaxine Succinate in Chinese Healthy Subjects Under Fasting and Fed States
M Wang, Y Yang, W Hu, Y Wang… - … in Drug Development, 2023 - Wiley Online Library
Desvenlafaxine succinate is a selective serotonin–norepinephrine reuptake inhibitor for the
treatment of major depressive disorder. The pharmacokinetic profile of desvenlafaxine …
treatment of major depressive disorder. The pharmacokinetic profile of desvenlafaxine …
[PDF][PDF] Application of Intranasal Administration in the Delivery of Antidepressant Active Ingredients. Pharmaceutics 2022, 14, 2070
Z Jin, Y Han, D Zhang, Z Li, Y Jing, B Hu, S Sun - 2022 - pdfs.semanticscholar.org
As a mental disease in modern society, depression shows an increasing occurrence, with
low cure rate and high recurrence rate. It has become the most disabling disease in the …
low cure rate and high recurrence rate. It has become the most disabling disease in the …
[PDF][PDF] A BRIEF REVIEW ON SLEEP PARALYSIS: MANAGEMENT AND TREATMENT
The brain alternates between wakefulness, nonrapid eye movement (NREM) sleep and
rapid eye movement (REM) sleep during sleep. Sleepwalking, sleep terrors, sleepwalking …
rapid eye movement (REM) sleep during sleep. Sleepwalking, sleep terrors, sleepwalking …